In hearings that took place this week, lawmakers grilled drug companies on their pricing plans for their potential vaccines, with some going so far as to ask executives at companies including Moderna, Johnson & Johnson, and AstraZeneca if they would supply their vaccines at cost.
While executives from other pharmaceutical companies also largely declined to agree to provide their potential vaccines at prices that would provide them with zero profits, the pressure from the Democratic Congress to do so appears to be rising.
Even shares of BioNTech -- which, along with its partner Pfizer, locked up a nearly $2 billion order for its COVID-19 vaccine candidate from the U.S. government on Wednesday -- saw its shares fall.
Investors could be growing concerned that future deals may be negotiated more fiercely, and potentially at prices that could make profits difficult to come by.
When someone comes with a vaccine, pay them as much as you can. They are saving lives.
Just a thought.
Investors could be growing concerned that future deals may be negotiated more fiercely, and potentially at prices that could make profits difficult to come by.
When someone comes with a vaccine, pay them as much as you can. They are saving lives.
Just a thought.
No comments:
Post a Comment